Payment overview · 2025
General Payments
$86.16
5 reported records · 5 companies
Healthcare provider profile · identity verified
Susan J Wright, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · OPELIKA, AL · NPI 1326120031
Verified facts
What the public records show
CMS Open Payments records show Susan J Wright, M.D. received $86.16 in general payments during 2025 across 5 reported records.
Amgen Inc. accounted for 22.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 7 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Farxiga by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Trelegy Ellipta by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $19.14 | 22.2% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $18.37 | 21.3% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $17.48 | 20.3% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $16.87 | 19.6% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $14.30 | 16.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $86.16 | 5 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $19.14 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $19.14 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $18.37 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $17.48 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $17.48 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $16.87 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $14.30 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 492 | 135 |
| Losartan Potassium | Losartan Potassium | 448 | 114 |
| Amlodipine Besylate | Amlodipine Besylate | 377 | 104 |
| Levothyroxine Sodium | Levothyroxine Sodium | 368 | 98 |
| Hydrochlorothiazide | Hydrochlorothiazide | 312 | 87 |
| Omeprazole | Omeprazole | 261 | 75 |
| Gabapentin | Gabapentin | 219 | 66 |
| Pantoprazole Sodium | Pantoprazole Sodium | 200 | 62 |
| Sertraline Hcl | Sertraline Hcl | 197 | 58 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 182 | 55 |
| Alprazolam | Alprazolam | 180 | 31 |
| Carvedilol | Carvedilol | 179 | 54 |
| Lisinopril | Lisinopril | 174 | 51 |
| Simvastatin | Simvastatin | 158 | 43 |
| Meloxicam | Meloxicam | 154 | 57 |
| Hydralazine Hcl | Hydralazine Hcl | 149 | 41 |
| Valsartan | Valsartan | 146 | 43 |
| Alendronate Sodium | Alendronate Sodium | 133 | 42 |
| Tramadol Hcl | Tramadol Hcl | 124 | 30 |
| Ozempic | Semaglutide | 122 | 18 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 120 | 17 |
| Potassium Chloride | Potassium Chloride | 102 | 27 |
| Raloxifene Hcl | Raloxifene Hcl | 101 | 29 |
| Metformin Hcl | Metformin Hcl | 99 | 32 |
| Trazodone Hcl | Trazodone Hcl | 99 | 26 |
| Metoprolol Succinate | Metoprolol Succinate | 98 | 29 |
| Pravastatin Sodium | Pravastatin Sodium | 93 | 26 |
| Furosemide | Furosemide | 87 | 31 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 85 | 24 |
| Citalopram Hbr | Citalopram Hydrobromide | 82 | 20 |
| Clonazepam | Clonazepam | 82 | 17 |
| Jardiance | Empagliflozin | 77 | 18 |
| Januvia | Sitagliptin Phosphate | 71 | 15 |
| Ezetimibe | Ezetimibe | 70 | 20 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 67 | 29 |
| Metformin Hcl Er | Metformin Hcl | 66 | 18 |
| Atenolol | Atenolol | 62 | 13 |
| Fluticasone Propionate | Fluticasone Propionate | 62 | 24 |
| Zolpidem Tartrate | Zolpidem Tartrate | 62 | 12 |
| Metoprolol Tartrate | Metoprolol Tartrate | 61 | 15 |
| Escitalopram Oxalate | Escitalopram Oxalate | 59 | 17 |
| Famotidine | Famotidine | 59 | 28 |
| Mounjaro | Tirzepatide | 56 | 13 |
| Bupropion Xl | Bupropion Hcl | 55 | 15 |
| Enalapril Maleate | Enalapril Maleate | 55 | 11 |
| Doxycycline Hyclate | Doxycycline Hyclate | 49 | 45 |
| Eliquis | Apixaban | 48 | 11 |
| Allopurinol | Allopurinol | 47 | 16 |
| Cephalexin | Cephalexin | 46 | 36 |
| Montelukast Sodium | Montelukast Sodium | 44 | 16 |
| Fluoxetine Hcl | Fluoxetine Hcl | 43 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 40 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 39 | 11 |
| Duloxetine Hcl | Duloxetine Hcl | 38 | 11 |
| Estradiol | Estradiol | 38 | 16 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 36 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 35 | suppressed |
| Memantine Hcl | Memantine Hcl | 34 | suppressed |
| Nystatin | Nystatin | 34 | 18 |
| Valacyclovir | Valacyclovir Hcl | 34 | 17 |
| Warfarin Sodium | Warfarin Sodium | 32 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 31 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 30 | suppressed |
| Glimepiride | Glimepiride | 28 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 28 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 27 | 27 |
| Synthroid | Levothyroxine Sodium | 26 | suppressed |
| Spironolactone | Spironolactone | 25 | 11 |
| Tamsulosin Hcl | Tamsulosin Hcl | 24 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 23 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 22 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 22 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 21 | 13 |
| Sumatriptan Succinate | Sumatriptan Succinate | 21 | suppressed |
| Bumetanide | Bumetanide | 20 | suppressed |
| Diazepam | Diazepam | 20 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 20 | suppressed |
| Prednisone | Prednisone | 20 | 13 |
| Tradjenta | Linagliptin | 20 | suppressed |
| Naproxen | Naproxen | 19 | suppressed |
| Repatha Sureclick | Evolocumab | 19 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 18 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Methylprednisolone | Methylprednisolone | 18 | 18 |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 17 | suppressed |
| Celecoxib | Celecoxib | 17 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 17 | 14 |
| Mupirocin | Mupirocin | 17 | 17 |
| Paxlovid | Nirmatrelvir/Ritonavir | 17 | 16 |
| Verapamil Er | Verapamil Hcl | 17 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 16 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 16 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 16 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 16 | suppressed |
| Lorazepam | Lorazepam | 16 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 16 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 16 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 15 | suppressed |
| Mirtazapine | Mirtazapine | 15 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 15 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 15 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 15 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 14 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Myrbetriq | Mirabegron | 14 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 13 | suppressed |
| Fluconazole | Fluconazole | 13 | suppressed |
| Klor-Con M20 | Potassium Chloride | 13 | suppressed |
| Ondansetron Odt | Ondansetron | 13 | suppressed |
| Primidone | Primidone | 13 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 12 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 12 | suppressed |
| Azithromycin | Azithromycin | 12 | 12 |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 12 | suppressed |
| Budesonide Ec | Budesonide | 12 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 12 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 12 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 12 | suppressed |
| Praluent Pen | Alirocumab | 12 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 12 | suppressed |
| Trulicity | Dulaglutide | 12 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 12 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 11 | suppressed |
| Dulera | Mometasone/Formoterol | 11 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 11 | suppressed |
| Eszopiclone | Eszopiclone | 11 | suppressed |
| Fenofibrate | Fenofibrate | 11 | suppressed |
| Finasteride | Finasteride | 11 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 11 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 11 | suppressed |
| Piroxicam | Piroxicam | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $86.16 · 5 records | Amgen Inc. | AREXVY, FARXIGA, FREESTYLE LIBRE 3, OTEZLA, REPATHA, SHINGRIX, VOQUEZNA | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error